Movement disorder specialist, lifestyle medicine physician and MJFF Principal Medical Advisor Rachel Dolhun, MD, DipABLM, shares tips on medication management for people at every stage of the disease journey. Like our podcasts? Please consider leaving a rating or review and sharing the series with your community. https://apple.co/3p02Jw0 The Founda…

If depression, anxiety or apathy occur as part of a Parkinson’s journey, it can be easy to feel alone, isolated or unsure of what might bring relief. But there are ways to manage these symptoms. Tune into audio from this Third Thursdays Webinar to hear people living with Parkinson’s share their stories of coping with mood changes as well as a movem…

Movement disorder specialist, lifestyle medicine physician and MJFF Principal Medical Advisor Rachel Dolhun, MD, DipABLM, answers community questions on Parkinson’s and exercise with physical therapist and rehab scientist Cristina Colón-Semenza, PhD. Listen to the audio or watch the video. Like our podcasts? Please consider leaving a rating or revi…

Being a care partner to someone with Parkinson’s disease (PD) can be a shifting and complex role, as symptoms and life circumstances change. And sometimes, this can lead to stress and even burnout for the care partner. Tune into audio from this Third Thursdays Webinar to hear expert panelists discuss how to navigate care partnership, including ever…

It is widely known that a healthy diet can provide essential nutrients and lead to a multitude of benefits, but growing evidence has highlighted important links between diet, nutrition, and brain health, particularly related to neurodegenerative disease. In this episode, Dr. Puja Agarwal discusses her research investigating the role that diet and n…

Parkinson's disease significantly impacts various aspects of communication, and this can make it challenging for people with the disease to communicate effectively, be understood by others, and engage in social situations. Dr. Gemma Moya-Galé joins this episode to talk about her work on voice and communication in people with Parkinson’s disease. In…

Understanding the biology of Parkinson’s disease (PD) and turning that knowledge into better treatments is a complex undertaking. In this episode of the award-winning Parkinson’s Science POV series, scientists at The Michael J. Fox Foundation (MJFF) discuss how they are tackling this problem from every angle. Whether it’s using cutting-edge imaging…

Certain populations are disproportionately affected by neurological diseases, including Parkinson's and other neurodegenerative diseases. A lot of work remains to be done to improve brain health outcomes and promote healthy brain aging across the lifespan, particularly for minoritized, underrepresented populations. Including participants from diver…

With two new drugs approved by the FDA, a National Plan signed into law and many advances in our understanding of Parkinson’s disease, 2024 has been a transformative year in Parkinson’s research. Tune into audio from this month’s Third Thursdays Webinar to hear research experts from industry and academia talk with MJFF staff about the latest resear…

Alpha-synuclein plays a key role in the pathophysiology of Parkinson's disease, and researchers have been investigating this protein as a therapeutic target and also as a potential biomarker for the disease. The alpha-synuclein seed amplification assay, developed by Dr. Claudio Soto and colleagues, leverages the self-replicating nature of the misfo…

Each person living with Parkinson’s disease (PD) will have a unique journey with their treatments, including the decision to have deep brain stimulation (DBS), which is a surgical procedure to treat Parkinson’s motor symptoms. While DBS isn’t suitable for everyone, it can be helpful in the right person, and it’s a complex, lifelong choice. And alth…

To help meet the growing global need for more movement disorders specialists, The Michael J. Fox Foundation created the Edmond J. Safra Fellowship in Movement Disorders in collaboration with longtime partner the Edmond J. Safra Foundation. This program supports the training of movement disorders specialists who will provide expert care and drive ad…

Troubles with gait – slow walking, shuffling steps and foot dragging and more – can be symptoms of Parkinson’s. In audio from this Third Thursdays Webinar, our experts explore the robust research efforts underway to understand and treat gait issues, from physical rehab interventions to deep brain stimulation modifications to wearable robots designe…

Stem cell models derived from patients with Parkinson’s disease are valuable tools that are helping researchers around the world to better understand the underlying causes of neurodegeneration and to develop biomarkers and new therapies. To maximize the potential impacts of these tools, it is critical that they are developed and shared according to…

In this podcast, four people from different backgrounds have a candid conversation on race, stigma and Parkinson’s. They share their experiences trying to find culturally competent medical professionals, overcoming the barriers to research participation, and communicating with their communities about their diagnosis. And they offer tips and advice …

New qualitative and quantitative tools are being developed to measure and track changes in proteins relevant for neurodegenerative disease, and these tools have the potential to accelerate drug discovery and clinical trials. In this episode, Dr. Judith Steen discusses her work creating novel qualitative and quantitative tools and workflows at the i…

Parkinson’s disease brings with it many potential symptoms, including hallucinations (seeing things that are not there) and delusions (believing things that are not true). Not everyone will experience these symptoms and not everyone who does will find them bothersome, but it can be a source of uncertainty and concern for people living with the dise…

Substantial research has focused on identifying biomarkers for the diagnosis of Parkinson's disease (PD) as well as monitoring progression of the disease. In developing these biomarkers, it is critical for scientists to consider how the biomarkers will ultimately be used in the clinic and in clinical trials research. In this interview, Dr. Charles …

Sleep disturbances, such as insomnia, sleep fragmentation, excessive daytime sleepiness, and REM sleep behavior disorder are common in people with Parkinson's disease (PD). Poor sleep quality can also impact other domains of function, including motor function. Prior research has shown that a type of photoreceptor cell in the retina, called melanops…

Finding the right Parkinson’s treatment plan can be a trial-and-error process. The kind of medication, the dosage, the timing and lifestyle factors are all important pieces of the puzzle. In audio from this Third Thursdays Webinar, our expert panel made up of people living with Parkinson’s disease (PD), a movement disorder specialist and a research…

Though existing evidence supports that dysfunction in the clearing of cellular debris plays an important role in the development of Parkinson's disease, many unanswered questions remain regarding the mechanisms of the autophagy-lysosomal pathway involved in this process. In particular, research in the field has been limited by a lack of reliable, q…

Research shows mindfulness and meditation can improve some Parkinson’s (PD) symptoms and help people live a better life with the disease, but it can be tricky to put into practice. In this podcast, you’ll hear from people whose lives have been touched by PD and who use mindfulness to reduce symptoms and stress, and from a researcher who is studying…

Evidence supports that dysfunction in the homeostasis of iron and other elements likely contributes to the pathophysiological mechanisms of Parkinson's disease, but we have yet to develop suitable elemental biomarkers for use in diagnosing and monitoring the progression of Parkinson's disease. Dr. Paul Lingor discusses his work in this area to iden…

The decision-making process around deep brain stimulation (DBS) to treat Parkinson’s motor symptoms can be a complex and emotional journey. People often have questions about when – and whether – to have the procedure and what the experience is like, from the months of evaluation pre-surgery to surgery day to life with the device. In audio from this…

Identifying reliable biomarkers for the diagnosis and prognosis of Parkinson's disease and atypical parkinsonism would have substantial impacts on clinical trials and clinical practice. A particularly active area of research is the development of novel molecular imaging biomarkers that can be used in combination with common neuroimaging approaches.…

Just over a year ago, there was a major breakthrough in Parkinson’s disease (PD) research – a tool that could detect abnormal alpha-synuclein protein in the spinal fluid of people living with PD even before onset of symptoms. This discovery is already impacting the ways scientists conduct and think about Parkinson’s research. Tune into this episode…

Prior studies have established links between poor olfaction and Parkinson's disease, and impaired sense of smell is a common prodromal symptom of Parkinson's disease. The causes and mechanisms of prodromal neurodegeneration are actively being researched. However, environmental exposure to pesticides or other chemicals may trigger or modify the cour…

You might be interested in stepping forward for science to play a role in the next breakthrough in Parkinson’s research, but still have questions about how to actually participate. How do you pick the right study for you? How do you balance your life logistics and your medical care considerations? What rights do you have when you participate in a s…

Gait impairments such as slow speed, small steps, and high variability from step to step are common in people with Parkinson's disease, and these changes begin to occur early in the course of disease. Freezing of gait may develop later for some individuals, and it has been linked to falls and other adverse outcomes. When the quality of walking decl…

Improving our understanding of the complex neural circuits involved in normal function of the basal ganglia and other parts of the brain impacted by Parkinson's disease is critical for developing more targeted and more effective treatment approaches. In this episode, Dr. Aryn Gittis discusses her research examining how the activity of specific basa…

Many people living with Parkinson’s disease (PD) experience pain as a non-motor symptom. Pain can arise from stiff muscles, dystonia, nerve pain and even the disease progression itself. It’s a symptom that some find difficult to talk about, but there are options for people to find relief. In audio from this Third Thursdays webinar, listen to our ex…

Demand for movement disorder specialists continues to grow, but not enough neurologists are receiving focused training in Parkinson’s and related conditions in order to meet the current and projected needs in the U.S. and around the world. In collaboration with longtime partner the Edmond J. Safra Foundation, The Michael J. Fox Foundation created t…

In this episode, hosted by Larry and Rebecca Gifford, members of The Michael J. Fox Foundation’s Patient Council and their care partners share their honest reactions to their diagnosis — from panic and denial to sadness and loneliness. This group of men and women of different ages and backgrounds offers words of wisdom about what to consider, what …

In this raw and emotional conversation, four women with Parkinson’s living in four different countries discuss the challenges faced because of delayed diagnosis, hormonal changes, lack of information and treatment, research inequity and gender biases. They share how they live better with the disease by advocating for themselves with their health ca…

Trichloroethylene (TCE) and related chemicals like perchloroethylene (PCE) have been used widely for a variety of commercial purposes over the past century, and these chemicals are prevalent in the air, water, and soil. Over the past several decades, mounting evidence has been published linking exposure to TCE/PCE with adverse health effects, inclu…

Living with Parkinson’s comes with a variety of symptoms, some of which can be unexpected, and frankly, embarrassing. Drooling, bladder issues and sexual dysfunction are hard to talk about, even with loved ones or your doctor – and can affect your self-image, your intimate relationships or the way you move through the world. In audio from this Thir…

For over a century, different surgical interventions have been explored to address symptoms of Parkinson's disease, and researchers are continuing to innovate and improve surgical treatments today. With new technology and an ever-expanding understanding of the function of the nervous system and the pathophysiology of Parkinson's disease, neurosurgi…

The Michael J. Fox Foundation for Parkinson's Research established its Research Tools Program to address gaps in the field and common challenges surrounding the development of reagents and models that slowed the initial stages of promising research projects. In collaboration with many partners and stakeholders, the Research Tools Program helps ensu…

The biology behind what causes Parkinson’s is complex, with only about a quarter of cases with clear genetic drivers. The environment – where you live, the air you breathe, the food you eat, the world around you – plays a key role in PD. Emerging research is showing environmental exposures to things like pesticides and pollution may interact with a…

Increasing evidence supports the presence of sex and gender differences in neurodegenerative conditions, including Alzheimer's disease and Parkinson's disease. There is a critical need to more closely examine sex and gender differences in all stages of research, therapeutic development, and clinical treatment to enable better outcomes through preci…

Atypical Parkinsonian Syndromes, such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and dementia with Lewy bodies are often initially diagnosed as Parkinson's disease. Incorrect, incomplete, or delayed diagnoses are barriers to beginning the most appropriate treatment early in the disease c…

The drug development pipeline is key to bringing new therapies to people with Parkinson’s disease (PD). With major breakthroughs in research in the past year, including a new biomarker for PD, The Michael J. Fox Foundation’s Parkinson’s Progression Markers Initiative (PPMI) study and other initiatives can be leveraged to create better designed tria…

For many years, Parkinson's disease and dementia with Lewy bodies have been defined using clinical features. With recent advances in biomarkers, particularly the alpha-synuclein seed amplification assay that allows us to detect misfolded and aggregated alpha-synuclein in cerebrospinal fluid, it is now possible to identify the presence of pathologic…

Dating and beginning new relationships with Parkinson’s involve distinct challenges, joys and fears. In this frank and funny podcast, our experts discuss how they face considerations like building and maintaining confidence, disease disclosure, and the importance of self-knowledge and self-care in new relationships. They remind us all that no matte…

There is a pressing need to develop safe and effective disease-modifying and symptomatic treatments for Parkinson's disease. Through improvements in our understanding of the pathophysiology of the disease, as well as genetic risk factors, new potential treatment targets have emerged. However, bringing a promising new compound from the lab through a…

We know exercise is important for people with Parkinson’s. Once you’ve decided to move more, what next? In this audio from our Third Thursdays Webinar, our experts discuss strategies for making exercise a meaningful part of your life. They present ways to make time for exercise and to make the most of it, including being aware of different types, f…

One key pillar of The Michael J. Fox Foundation’s research strategy is a focus on “de-risking" potential treatments for Parkinson’s disease. This episode of our award-winning “Parkinson’s Science POV” series explains how lowering the risk associated with developing new therapies leads to a more robust pipeline of treatments. The episode details sev…

In neurodegenerative conditions such as Parkinson's disease (PD), patients often do not receive a diagnosis until the hallmark motor symptoms begin to manifest. This can be a decade or more after substantial changes start occurring in the brain. A major goal of the PD research field has been to develop methods for earlier detection and intervention…

Doctors have been using DaTscan brain imaging as a tool to help diagnose the Parkinson’s disease (PD) for more than a decade, but even people who know a lot about the disease often still have questions about its role — and the role of other imaging tools — in diagnosis and care. What’s a DaTscan, and how does it relate to PET, SPECT and MRI? When i…

A substantial portion of people with Parkinson's disease (PD) have a family history of the disease, and new findings continue to improve our understanding of relevant genetic variants. These discoveries are key for clarifying the mechanisms that lead to Parkinson's disease as well as the development of new therapies. The Global Parkinson's Genetics…